Great Lakes Advisors LLC Has $3.63 Million Position in Intellia Therapeutics Inc (NTLA)

Great Lakes Advisors LLC lowered its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 7.3% in the third quarter, HoldingsChannel reports. The firm owned 126,845 shares of the company’s stock after selling 10,033 shares during the quarter. Great Lakes Advisors LLC’s holdings in Intellia Therapeutics were worth $3,630,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Intellia Therapeutics by 12.2% during the third quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock worth $75,934,000 after purchasing an additional 287,682 shares in the last quarter. Rehmann Capital Advisory Group acquired a new position in shares of Intellia Therapeutics during the third quarter worth $14,409,000. Teachers Advisors LLC grew its stake in shares of Intellia Therapeutics by 36.0% during the third quarter. Teachers Advisors LLC now owns 80,417 shares of the company’s stock worth $2,302,000 after purchasing an additional 21,286 shares in the last quarter. Neuberger Berman Group LLC grew its stake in shares of Intellia Therapeutics by 12.9% during the third quarter. Neuberger Berman Group LLC now owns 73,390 shares of the company’s stock worth $2,100,000 after purchasing an additional 8,405 shares in the last quarter. Finally, Farmhouse Investment Management LLC grew its stake in shares of Intellia Therapeutics by 63.8% during the third quarter. Farmhouse Investment Management LLC now owns 68,800 shares of the company’s stock worth $1,969,000 after purchasing an additional 26,800 shares in the last quarter. Hedge funds and other institutional investors own 67.80% of the company’s stock.

A number of equities analysts recently commented on NTLA shares. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, September 28th. Chardan Capital reissued a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research report on Friday, August 24th. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Thursday, October 18th. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Wednesday, October 31st. Finally, Zacks Investment Research cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Intellia Therapeutics presently has an average rating of “Hold” and a consensus price target of $33.42.

Shares of NTLA opened at $18.29 on Tuesday. Intellia Therapeutics Inc has a 1-year low of $15.70 and a 1-year high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Intellia Therapeutics had a negative net margin of 308.81% and a negative return on equity of 31.70%. The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $11.58 million. During the same period last year, the firm earned ($0.44) earnings per share. Intellia Therapeutics’s revenue was up 1.2% on a year-over-year basis. Sell-side analysts forecast that Intellia Therapeutics Inc will post -2.09 EPS for the current fiscal year.

WARNING: “Great Lakes Advisors LLC Has $3.63 Million Position in Intellia Therapeutics Inc (NTLA)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2018/12/04/great-lakes-advisors-llc-has-3-63-million-position-in-intellia-therapeutics-inc-ntla.html.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Recommended Story: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit